We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 19.00 | 1.07% | 1,799.50 | 1,796.00 | 1,796.50 | 1,799.50 | 1,780.00 | 1,784.00 | 9,804,173 | 16:35:21 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 15.00 | 73.94B |
From May 2019 to May 2024
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) said Thursday that it had sold the rights to its drug candidate tapinarof for up to 250 million pounds ($331 million) to Roivant Sciences.
The pharmaceutical major said that the deal includes an initial payment of GBP150 million plus a potential future milestone payment of GBP100 million.
Roivant will acquire the rights for the drug worldwide, with the exception of China, GSK said.
"We have taken a strategic decision to divest or partner medicines in our R&D portfolio that are a better fit for other companies, allowing us to concentrate our resources on other promising assets," said John Lepore, senior vice president, R&D pipeline at GSK.
Tapinarof is a drug being developed for the treatment of psoriasis and atopic dermatitis.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
July 12, 2018 10:20 ET (14:20 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
